Skip to main
ENOV

Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis Corp (ENOV) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enovis is a medical technology company with a compelling product portfolio and strong market positioning, which is reflected in its solid financial results and steady growth in the Prevention & Recovery segment. Despite potential risks, such as slower-than-expected top-line growth and tariff pressures, the company's significant investments in new product development and M&A integration are expected to drive further growth and margin expansion. As a result, the company's current valuation is perceived as too low and we see potential for multiple expansion as Enovis continues to deliver above market growth.

Bears say

Enovis is facing multiple headwinds, including softer Western Europe volumes, Middle East conflict, and higher inflationary headwinds, resulting in a projected decline in revenue growth for the fiscal year 2026. The company also has a high debt level and is reliant on cross-selling opportunities and new product launches for future growth, which may not materialize. Additionally, competition in key segments of the company's end-markets and potential tariff exposure also pose risks that could impact the company's financial performance. Overall, these factors contribute to a negative outlook on Enovis's stock.

Enovis Corp (ENOV) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enovis Corp (ENOV) Forecast

Analysts have given Enovis Corp (ENOV) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Enovis Corp (ENOV) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enovis Corp (ENOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.